Some celebrities are showing off their carpeted bathrooms, but does this mean we should add carpet into one of the wettest ...

It all started with a book: MASH: A Novel About Three Army Doctors, published in 1968. This was adapted into the 1970 feature film, nominated for five Oscars and winning for Best Adapted Screenplay.

The scientists at Miramax have apparently been working in the lab late at night coming up with an idea for an eerie sight. And what they’ve come up with is adapting someone else’s. The studio is ...

EXCLUSIVE: The 1962 song “Monster Mash,” which has become an annual Halloween +hit, is becoming an animated movie at Miramax. Miramax CEO Jonathan Glickman, who has been behind such haunted hits as ...

“Monster Mash” by Bobby “Boris” Pickett and the Crypt-Kickers has just been crowned the biggest Halloween song of all time by Billboard! The iconic hit was first released in August 1962, and spent two ...

After a decade operating at The Rim shopping center, Mash’D — a restaurant and bar specializing in “Rebellious American” fare — will shut down Wednesday, Oct. 29, according to a social media post. In ...

For years, MASH was where drug development dreams went to die. One trial after another failed. Companies bowed out. The field earned a reputation as one of biopharma’s most intractable challenges: a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Metabolic-associated steatohepatitis (MASH) happens when excess fat in the liver causes inflammation and scarring, or fibrosis. The condition is serious, and when left untreated it can lead to ...

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...